MedTrace Logo

Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment

NCT00182429 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-08-15

No results posted yet for this study

Summary

What is the difference between the use of one drug (Oral Metronidazole) versus the use of this same drug combined with another drug (Rifampin) in treatment of bacteria and infection-associated diarrhea in patients? This infection is an important cause of morbidity and mortality in both the community and hospitals, and the leading cause of hospital and chronic facility-acquired diarrhea. Research is important for the treatment of this infection. Patient care with use of two medication treatment regimens will be studied.

Conditions

  • Clostridium Enterocolitis
  • Antibiotic-Associated Diarrhea
  • Pseudomembranous Colitis
  • Pseudomembranous Enterocolitis
  • Pseudomembranous Enteritis

Interventions

DRUG

Metronidazole and Rifampin

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • McMaster University

    lead OTHER

Principal Investigators

  • Christine H Lee, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2005-04-30
Completion
2005-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00182429 on ClinicalTrials.gov